Form 4: Atea Pharmaceuticals Director Franklin M. Berger Reports Significant Equity Compensation Grants

Atea Pharmaceuticals, Inc. Director Franklin M. Berger reported the acquisition of 29,600 shares of common stock through RSU vesting, alongside new grants of 29,600 restricted stock units and 41,200 stock options.

Summary

• Franklin M. Berger, a Director of Atea Pharmaceuticals, Inc. (AVIR), reported changes in his beneficial ownership of company securities.
• On June 20, 2025, Mr. Berger acquired 29,600 shares of common stock at a price of $0.00 per share, resulting from the vesting of previously granted restricted stock units.
• Following this transaction, Mr. Berger beneficially owns 506,497 shares of common stock directly.
• Concurrently, Mr. Berger was granted 29,600 new Restricted Stock Units (RSUs) at a price of $0.00 per unit.
• These new RSUs are set to vest in a single installment on the earlier of the next annual meeting of stockholders or the first anniversary of the grant date (June 20, 2025), subject to continued service.
• Additionally, Mr. Berger was granted 41,200 new Stock Options with an exercise price of $3.25 per share, also at a reported price of $0.00.
• These stock options will vest and become exercisable in twelve substantially equal monthly installments following June 20, 2025, becoming fully vested on the first anniversary of the grant date, subject to continued service.
• The stock options have an expiration date of June 19, 2035.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it indicates a director receiving equity compensation, which aligns their interests with shareholders and is a normal part of compensation. It's not strongly positive as it's a routine event rather than a significant new development.

Positives

• The grants of new Restricted Stock Units (29,600 units) and Stock Options (41,200 options) align the director's interests with long-term shareholder value.
• The vesting of 29,600 previously granted RSUs into common stock demonstrates the realization of prior equity compensation and increases the director's direct ownership stake.

Future Outlook

The document indicates future vesting schedules for the newly granted Restricted Stock Units and Stock Options, with vesting periods extending up to one year from the grant date (June 20, 2025), contingent on the director's continued service.

Industry Context

This Form 4 filing represents a routine equity compensation event for a director in a publicly traded biotechnology or pharmaceutical company. Such grants are common practice to incentivize and retain key personnel, aligning their financial interests with the company's long-term performance and shareholder value creation. The specific terms of the grants (e.g., vesting schedules, exercise price) are typical for director compensation packages in the industry.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) and Stock Options to a director is a standard practice in the biotechnology and pharmaceutical industry for executive and board compensation, aiming to align interests with long-term company performance.
• The vesting schedule for RSUs (single installment on earlier of next annual meeting or first anniversary) and stock options (12 monthly installments over one year) is consistent with common industry practices for director equity awards, promoting retention and sustained engagement.
• The exercise price of $3.25 for the stock options, when granted at a reported price of $0.00, suggests the options were granted at fair market value on the grant date, which is a common and compliant method for incentive stock options.

Related Party Transactions

• The reported transactions involve equity compensation granted by Atea Pharmaceuticals, Inc. to Franklin M. Berger, a Director of the company, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The grant of new equity awards (RSUs and stock options) may result in minor future dilution upon vesting and exercise, but also serves to align the director's interests with long-term shareholder value creation.
• Employees (specifically the director): Franklin M. Berger benefits directly from the equity compensation, which incentivizes continued service and performance.

Next Steps

• The newly granted Restricted Stock Units are expected to vest in a single installment on the earlier of the next annual meeting of Atea Pharmaceuticals' stockholders or June 20, 2026.
• The newly granted stock options will vest in twelve substantially equal monthly installments following June 20, 2025, becoming fully vested by June 20, 2026.

Key Dates

Keywords

Atea Pharmaceuticals, AVIR, Franklin M. Berger, SEC Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Compensation, Director Compensation, Beneficial Ownership